Radiosensitization of the RIF-1 murine flank tumor by desmethylmisonidazole (Ro 05 9963) during interstitial brachytherapy.

Abstract

We have investigated the interaction of the nitroimidazole radiosensitizer desmethylmisonidazole (Ro 05 9963) with interstitial radiation using a clonogenic cell assay as the endpoint. Removable I-125 sources were implanted at right angles to the outer surface of globular RIF-1 tumors grown in the flanks of C3H/He mice. Desmethylmisonidazole was administered by continuous intraperitoneal infusion at a rate of 2.7 mg/gm body weight /24 hr. Tumor and serum drug levels were measured by high performance liquid chromatography. Tumor drug levels of 40--100 mugm/gm tumor tissue were achieved consistently. No appreciable cytotoxicity was produced by desmethylmisonidazole alone, but a radiosensitization effect with a dose modifying factor of 1.6 was found.

• Authors: M Bernstein, P H Gutin, D F Deen, K A Weaver, V A Levin, M H Barcellos
• Journal: International journal of radiation oncology, biology, physics (Int J Radiat Oncol Biol Phys) 1982 Mar-Apr Vol. 8 Issue 3-4 Pg. 487-90 ISSN: 0360-3016 [Print] United States
• PMID: 7107372 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Nitroimidazoles
• Radiation-Sensitizing Agents
• Misonidazole
• desmethylmisonidazole

Topics

• Animals
• Brachytherapy
• Cell Survival (drug effects)
• Colony-Forming Units Assay
• Female
• Mice
• Misonidazole (analogs & derivatives, pharmacology)
• Neoplasms, Experimental (radiotherapy)
• Nitroimidazoles (pharmacology)
• Radiation-Sensitizing Agents
• Radiotherapy Dosage